{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:53:37Z","timestamp":1792263217017,"version":"4.4.0"},"reference-count":184,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Obesity rates are increasing worldwide and there is a need for novel therapeutic treatment options. The endocannabinoid system has been linked to homeostatic processes, including metabolism, food intake, and the regulation of body weight. Rimonabant, an inverse agonist for the cannabinoid CB1 receptor, was effective at producing weight loss in obese subjects. However, due to adverse psychiatric side effects, rimonabant was removed from the market. More recently, we reported an inverse relationship between cannabis use and BMI, which has now been duplicated by several groups. As those results may appear contradictory, we review here preclinical and clinical studies that have studied the impact on body weight of various cannabinoid CB1 drugs. Notably, we will review the impact of CB1 inverse agonists, agonists, partial agonists, and neutral antagonists. Those findings clearly point out the cannabinoid CB1 as a potential effective target for the treatment of obesity. Recent preclinical studies suggest that ligands targeting the CB1 may retain the therapeutic potential of rimonabant without the negative side effect profile. Such approaches should be tested in clinical trials for validation.<\/jats:p>","DOI":"10.3390\/biom10060855","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T03:32:21Z","timestamp":1591327941000},"page":"855","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs"],"prefix":"10.3390","volume":"10","author":[{"given":"Thomas","family":"Murphy","sequence":"first","affiliation":[{"name":"Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, University of Toronto, 33 Russell Street, Toronto, ON M5S 2S1, Canada"},{"name":"Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6406-4973","authenticated-orcid":false,"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[{"name":"Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, University of Toronto, 33 Russell Street, Toronto, ON M5S 2S1, Canada"},{"name":"Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada"},{"name":"Acute Care Program, Centre for Addiction and Mental Health, Toronto, ON M6J 1H4, Canada"},{"name":"Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON M5S 2S1, Canada"},{"name":"Department of Family and Community Medicine, University of Toronto, Toronto, ON M5G 1V7, Canada"},{"name":"Department of Psychiatry, Division of Brain and Therapeutics, University of Toronto, Toronto, ON M5T 1R8, Canada"},{"name":"Institute of Medical Sciences, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2020, January 15). Obesity and Overweight. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","article-title":"Trends in adult body-mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population-based measurement studies with 19.2 million participants","volume":"387","author":"Collaboration","year":"2016","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pop.2015.08.013","article-title":"Economic Impact of Obesity","volume":"43","author":"Spieker","year":"2016","journal-title":"Prim. Care"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/pbc.23367","article-title":"The endocannabinoid system: Role in energy regulation","volume":"58","author":"Gamage","year":"2012","journal-title":"Pediatric Blood Cancer"},{"key":"ref_5","first-page":"241","article-title":"Endocannabinoids Part I: Molecular basis of endocannabinoid formation, action and inactivation and development of selective inhibitors","volume":"5","author":"Bisogno","year":"2001","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrn1247","article-title":"The molecular logic of endocannabinoid signalling","volume":"4","author":"Piomelli","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/oxfordjournals.jbchem.a003200","article-title":"Cannabinoid receptors and their endogenous ligands","volume":"132","author":"Sugiura","year":"2002","journal-title":"J. Biochem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33302","DOI":"10.1038\/srep33302","article-title":"Human CB1 Receptor Isoforms, present in Hepatocytes and beta-cells, are Involved in Regulating Metabolism","volume":"6","author":"Doyle","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainres.2005.11.035","article-title":"Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain","volume":"1071","author":"Gong","year":"2006","journal-title":"Brain Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nature23272","article-title":"Crystal structures of agonist-bound human cannabinoid receptor CB1","volume":"547","author":"Hua","year":"2017","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB(1) and CB(2)","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cmet.2013.03.001","article-title":"The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders","volume":"17","author":"Silvestri","year":"2013","journal-title":"Cell Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00125-008-1178-6","article-title":"Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: Associations with changes in metabolic risk factors","volume":"52","author":"Cote","year":"2009","journal-title":"Diabetologia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/sj.ijo.0803539","article-title":"Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men","volume":"31","author":"Cote","year":"2007","journal-title":"Int. J. Obes. (Lond.)"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Horn, H., Bohme, B., Dietrich, L., and Koch, M. (2018). Endocannabinoids in Body Weight Control. Pharmaceuticals, 11.","DOI":"10.3390\/ph11020055"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pharmthera.2009.12.005","article-title":"Cannabinoids and the gut: New developments and emerging concepts","volume":"126","author":"Izzo","year":"2010","journal-title":"Pharm. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/dom.12646","article-title":"Endocannabinoid regulation of beta-cell functions: Implications for glycaemic control and diabetes","volume":"18","author":"Jourdan","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1463-1326.2009.01133.x","article-title":"Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes","volume":"12","author":"Perwitz","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Rossi, F., Punzo, F., Umano, G.R., Argenziano, M., and Miraglia Del Giudice, E. (2018). Role of Cannabinoids in Obesity. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092690"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0091-3057(86)90144-9","article-title":"Behavioral analysis of marijuana effects on food intake in humans","volume":"25","author":"Foltin","year":"1986","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00213-010-1995-4","article-title":"Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: A controlled laboratory study","volume":"212","author":"Bedi","year":"2010","journal-title":"Psychopharmacology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00213-005-2242-2","article-title":"Dronabinol and marijuana in HIV(+) marijuana smokers: Acute effects on caloric intake and mood","volume":"181","author":"Haney","year":"2005","journal-title":"Psychopharmacology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00008877-200509000-00009","article-title":"Delta9-THC induced hyperphagia and tolerance assessment: Interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats","volume":"16","author":"Jarbe","year":"2005","journal-title":"Behav. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"PL113","DOI":"10.1016\/S0024-3205(98)00322-1","article-title":"Appetite suppression and weight loss after the cannabinoid antagonist SR 141716","volume":"63","author":"Colombo","year":"1998","journal-title":"Life Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00213-005-2171-0","article-title":"The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats","volume":"180","author":"McLaughlin","year":"2005","journal-title":"Psychopharmacology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/aje\/kwr200","article-title":"Obesity and cannabis use: Results from 2 representative national surveys","volume":"174","year":"2011","journal-title":"Am. J. Epidemiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/00952990.2010.500438","article-title":"Cannabis use and obesity and young adults","volume":"36","author":"Hayatbakhsh","year":"2010","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1079\/PHN2000114","article-title":"Dietary intake and nutritional status of US adult marijuana users: Results from the Third National Health and Nutrition Examination Survey","volume":"4","author":"Smit","year":"2001","journal-title":"Public Health Nutr."},{"key":"ref_30","first-page":"9","article-title":"Metabolic Effects of Marijuana Use among Blacks","volume":"4","author":"Racine","year":"2015","journal-title":"J. Dis. Glob. Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.mehy.2013.01.019","article-title":"Cannabis and Delta9-tetrahydrocannabinol (THC) for weight loss?","volume":"80","author":"Trigo","year":"2013","journal-title":"Med. Hypotheses"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/S1516-44462009000200012","article-title":"The psychiatric side-effects of rimonabant","volume":"31","author":"Moreira","year":"2009","journal-title":"Rev. Bras. De Psiquiatr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3389\/fphar.2018.00786","article-title":"Long-Term Stress and Concomitant Marijuana Smoke Exposure Affect Physiology, Behavior and Adult Hippocampal Neurogenesis","volume":"9","author":"Rusznak","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/ijo.2008.3","article-title":"Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats","volume":"32","author":"Kunz","year":"2008","journal-title":"Int. J. Obes. (Lond.)"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"E1311","DOI":"10.1152\/ajpendo.90972.2008","article-title":"Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs","volume":"296","author":"Richey","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/ijo.2008.105","article-title":"Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant","volume":"32","author":"Herling","year":"2008","journal-title":"Int. J. Obes. (Lond.)"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejphar.2006.10.028","article-title":"Antidepressant-induced undesirable weight gain: Prevention with rimonabant without interference with behavioral effectiveness","volume":"554","author":"Gobshtis","year":"2007","journal-title":"Eur. J. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/adb.12056","article-title":"The inverse agonist of CB1 receptor SR141716 blocks compulsive eating of palatable food","volume":"19","author":"Dore","year":"2014","journal-title":"Addict. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1007\/s00125-011-2302-6","article-title":"Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice","volume":"54","author":"Bajzer","year":"2011","journal-title":"Diabetologia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1096\/fj.13-247643","article-title":"Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity","volume":"28","author":"Boon","year":"2014","journal-title":"FASEB J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1210\/en.2014-1730","article-title":"Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats","volume":"156","author":"Karlsson","year":"2015","journal-title":"Endocrinology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.euroneuro.2017.03.010","article-title":"Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats","volume":"27","author":"Lazzari","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Muller, G.A., Herling, A.W., Wied, S., and Muller, T.D. (2020). CB1 Receptor-Dependent and Independent Induction of Lipolysis in Primary Rat Adipocytes by the Inverse Agonist Rimonabant (SR141716A). Molecules, 25.","DOI":"10.3390\/molecules25040896"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Chang, E., Kim, D.H., Yang, H., Lee, D.H., Bae, S.H., and Park, C.Y. (2018). CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0206152"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"15645","DOI":"10.1038\/s41598-017-15154-6","article-title":"Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity","volume":"7","author":"Chitrala","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/oby.2011.357","article-title":"Effects of chronic oral rimonabant administration on energy budgets of diet-induced obese C57BL\/6 mice","volume":"20","author":"Zhang","year":"2012","journal-title":"Obesity"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1134\/S0006297918100127","article-title":"Inhibition of Cannabinoid Receptor 1 Can Influence the Lipid Metabolism in Mice with Diet-Induced Obesity","volume":"83","author":"Wei","year":"2018","journal-title":"Biochem. (Mosc)"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7669","DOI":"10.1074\/jbc.RA118.005094","article-title":"Role of microRNA in CB1 antagonist-mediated regulation of adipose tissue macrophage polarization and chemotaxis during diet-induced obesity","volume":"294","author":"Miranda","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e6141","DOI":"10.1590\/1414-431x20176141","article-title":"Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice","volume":"50","author":"Chen","year":"2017","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1124\/jpet.106.118737","article-title":"Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents","volume":"321","author":"Fong","year":"2007","journal-title":"J. Pharm. Exp."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/j.1471-4159.2009.06549.x","article-title":"Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant","volume":"112","author":"Burokas","year":"2010","journal-title":"J. Neurochem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0014-2999(03)01343-8","article-title":"Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice","volume":"462","author":"Hildebrandt","year":"2003","journal-title":"Eur. J. Pharm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0031-9384(04)00302-6","article-title":"Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat","volume":"82","author":"Chambers","year":"2004","journal-title":"Physiol. Behav."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1476-5381.2008.00107.x","article-title":"Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice","volume":"156","author":"Riedel","year":"2009","journal-title":"Br. J. Pharm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1677\/JOE-09-0210","article-title":"Responses to the cannabinoid receptor-1 antagonist, AM251, are more robust with age and with high-fat feeding","volume":"203","author":"Judge","year":"2009","journal-title":"J. Endocrinol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.metabol.2013.06.011","article-title":"Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats","volume":"62","author":"Merroun","year":"2013","journal-title":"Metabolism"},{"key":"ref_57","first-page":"487","article-title":"The effects of leptin in combination with a cannabinoid receptor 1 antagonist, AM 251, or cannabidiol on food intake and body weight in rats fed a high-fat or a free-choice high sugar diet","volume":"65","author":"Wolak","year":"2014","journal-title":"J. Physiol. Pharm."},{"key":"ref_58","first-page":"457","article-title":"The inhibitory effect of combination treatment with leptin and cannabinoid CB1 receptor agonist on food intake and body weight gain is mediated by serotonin 1B and 2C receptors","volume":"67","author":"Wolak","year":"2016","journal-title":"J. Physiol. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1421420112","article-title":"A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome","volume":"112","author":"Bowles","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","first-page":"181","article-title":"Interaction between orexin A and cannabinoid system in the lateral hypothalamus of rats and effects of subchronic intraperitoneal administration of cannabinoid receptor inverse agonist on food intake and the nutritive utilization of protein","volume":"66","author":"Merroun","year":"2015","journal-title":"J. Physiol. Pharm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1530\/JOE-15-0004","article-title":"Chronic administration of AM251 improves albuminuria and renal tubular structure in obese rats","volume":"225","author":"Jenkin","year":"2015","journal-title":"J. Endocrinol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3389\/fimmu.2019.01049","article-title":"Cannabinoid Receptor 1 Blockade Attenuates Obesity and Adipose Tissue Type 1 Inflammation Through miR-30e-5p Regulation of Delta-Like-4 in Macrophages and Consequently Downregulation of Th1 Cells","volume":"10","author":"Miranda","year":"2019","journal-title":"Front. Immunol"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/syn.21721","article-title":"Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: A PET study","volume":"68","author":"Takano","year":"2014","journal-title":"Synapse"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fphar.2019.00207","article-title":"The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice","volume":"10","author":"Micale","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1096\/fj.201801152RR","article-title":"A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice","volume":"33","author":"Han","year":"2019","journal-title":"FASEB J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/dom.13350","article-title":"Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity","volume":"20","author":"Han","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2012.07.002","article-title":"Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance","volume":"16","author":"Tam","year":"2012","journal-title":"Cell Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bph.14849","article-title":"Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease","volume":"177","author":"Udi","year":"2020","journal-title":"Br. J. Pharm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"104483","DOI":"10.1016\/j.yrtph.2019.104483","article-title":"Preclinical toxicity evaluation of JD5037, a peripherally restricted CB1 receptor inverse agonist, in rats and dogs for treatment of nonalcoholic steatohepatitis","volume":"109","author":"Kale","year":"2019","journal-title":"Regul. Toxicol. Pharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/dom.12447","article-title":"A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis","volume":"17","author":"Hsiao","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3389\/fphar.2017.00707","article-title":"Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice","volume":"8","author":"Chen","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pbb.2015.06.007","article-title":"ENP11, a potential CB1R antagonist, induces anorexia in rats","volume":"135","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"10276","DOI":"10.1021\/acs.jmedchem.8b01467","article-title":"6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity","volume":"61","author":"Zhang","year":"2018","journal-title":"J. Med. Chem"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0014-2999(01)00873-1","article-title":"Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2","volume":"416","author":"Aceto","year":"2001","journal-title":"Eur. J. Pharm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/j.1365-2982.2009.01315.x","article-title":"Selective lack of tolerance to delayed gastric emptying after daily administration of WIN 55,212-2 in the rat","volume":"21","author":"Abalo","year":"2009","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/nmo.12073","article-title":"Cannabinoids may worsen gastric dysmotility induced by chronic cisplatin in the rat","volume":"25","author":"Abalo","year":"2013","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/FBP.0000000000000018","article-title":"Concurrent pharmacological modification of cannabinoid-1 and glucagon-like peptide-1 receptor activity affects feeding behavior and body weight in rats fed a free-choice, high-carbohydrate diet","volume":"25","author":"Radziszewska","year":"2014","journal-title":"Behav. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6","DOI":"10.12659\/MSMBR.883726","article-title":"Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2","volume":"19","author":"Radziszewska","year":"2013","journal-title":"Med. Sci. Monit. Basic Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/npp.2013.292","article-title":"Cannabinoid receptor activation prevents the effects of chronic mild stress on emotional learning and LTP in a rat model of depression","volume":"39","author":"Segev","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"ref_80","first-page":"394","article-title":"The effect of spinally administered WIN 55,212-2, a cannabinoid agonist, on thermal pain sensitivity in diabetic rats","volume":"19","author":"Jahanabadi","year":"2016","journal-title":"Iran. J. Basic Med. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3389\/fphys.2019.00704","article-title":"Cannabinoid CB1 Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced Obesity","volume":"10","author":"Argueta","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"173087","DOI":"10.1016\/j.ejphar.2020.173087","article-title":"Win 55,212-2, atenolol and subdiaphragmatic vagotomy prevent acceleration of gastric emptying induced by cachexia via Yoshida-AH-130 cells in rats","volume":"877","author":"Silva","year":"2020","journal-title":"Eur. J. Pharm."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s11064-009-9914-y","article-title":"HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat","volume":"34","author":"Dalton","year":"2009","journal-title":"Neurochem. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0014-2999(00)00069-8","article-title":"Effects of the cannabinoid receptor agonist, HU 210, on ingestive behaviour and body weight of rats","volume":"391","author":"Giuliani","year":"2000","journal-title":"Eur. J. Pharm."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000026416","article-title":"Maternal exposure to the synthetic cannabinoid HU-210: Effects on the endocrine and immune systems of the adult male offspring","volume":"7","author":"Munoz","year":"2000","journal-title":"Neuroimmunomodulation"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1111\/bph.13892","article-title":"Cannabinoid CB1 \/CB2 receptor agonists attenuate hyperactivity and body weight loss in a rat model of activity-based anorexia","volume":"174","author":"Scherma","year":"2017","journal-title":"Br. J. Pharm."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2131\/jts.40.739","article-title":"Cannabidiol-2\u2019,6\u2019-dimethyl ether stimulates body weight gain in apolipoprotein E-deficient BALB\/c. KOR\/Stm Slc-Apoe(shl) mice","volume":"40","author":"Takeda","year":"2015","journal-title":"J. Toxicol. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.euroneuro.2010.04.002","article-title":"Activity-based anorexia in C57\/BL6 mice: Effects of the phytocannabinoid, Delta9-tetrahydrocannabinol (THC) and the anandamide analogue, OMDM-2","volume":"20","author":"Lewis","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/npp.2011.19","article-title":"The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia","volume":"36","author":"Verty","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1055\/s-0031-1297940","article-title":"The major plant-derived cannabinoid Delta(9)-tetrahydrocannabinol promotes hypertrophy and macrophage infiltration in adipose tissue","volume":"44","author":"Wong","year":"2012","journal-title":"Horm. Metab. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/cbf.3058","article-title":"Oxidative stress and cannabinoid receptor expression in type-2 diabetic rat pancreas following treatment with Delta(9)-THC","volume":"32","author":"Coskun","year":"2014","journal-title":"Cell Biochem. Funct."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.neuroscience.2015.07.024","article-title":"Strain and sex differences in puberty onset and the effects of THC administration on weight gain and brain volumes","volume":"305","author":"Keeley","year":"2015","journal-title":"Neuroscience"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Cluny, N.L., Keenan, C.M., Reimer, R.A., Le Foll, B., and Sharkey, K.A. (2015). Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Delta9-Tetrahydrocannabinol. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144270"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Marcus, D.J., Zee, M.L., Davis, B.J., Haskins, C.P., Andrews, M.J., Amin, R., Henderson-Redmond, A.N., Mackie, K., Czyzyk, T.A., and Morgan, D.J. (2016). Mice Expressing a \u201cHyper-Sensitive\u201d Form of the Cannabinoid Receptor 1 (CB1) Are Neither Obese Nor Diabetic. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160462"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jphp.13042","article-title":"The protective effects of Delta(9) -tetrahydrocannabinol against inflammation and oxidative stress in rat liver with fructose-induced hyperinsulinemia","volume":"71","author":"Beydogan","year":"2019","journal-title":"J. Pharm. Pharm."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bph.14856","article-title":"Lasting effects of repeated (9) -tetrahydrocannabinol vapour inhalation during adolescence in male and female rats","volume":"177","author":"Nguyen","year":"2020","journal-title":"Br. J. Pharm."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1111\/bph.14797","article-title":"The novel cannabinoid CB1 receptor agonist AM11101 increases food intake in female rats","volume":"176","author":"Ogden","year":"2019","journal-title":"Br. J. Pharm."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.neuropharm.2006.03.029","article-title":"Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21","volume":"51","author":"Pavon","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/j.1476-5381.2011.01698.x","article-title":"Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats","volume":"165","author":"Alonso","year":"2012","journal-title":"Br. J. Pharm."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ejphar.2008.02.029","article-title":"Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor","volume":"584","author":"Chen","year":"2008","journal-title":"Eur. J. Pharm."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1038\/s41598-017-03292-w","article-title":"The cannabinoid ligand LH-21 reduces anxiety and improves glucose handling in diet-induced obese pre-diabetic mice","volume":"7","author":"Rafacho","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fendo.2018.00167","article-title":"LH-21, A Peripheral Cannabinoid Receptor 1 Antagonist, Exerts Favorable Metabolic Modulation Including Antihypertensive Effect in KKAy Mice by Regulating Inflammatory Cytokines and Adipokines on Adipose Tissue","volume":"9","author":"Dong","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1476-5381.2010.00908.x","article-title":"A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents","volume":"161","author":"Cluny","year":"2010","journal-title":"Br. J. Pharm."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1172\/JCI42551","article-title":"Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity","volume":"120","author":"Tam","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fphar.2018.00156","article-title":"Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice","volume":"9","author":"Ma","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"R2185","DOI":"10.1152\/ajpregu.00663.2007","article-title":"A neutral CB1 receptor antagonist reduces weight gain in rat","volume":"293","author":"Chambers","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/sj.npp.1301476","article-title":"The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats","volume":"33","author":"Sink","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.pbb.2010.10.013","article-title":"The neutral cannabinoid CB(1) receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat","volume":"97","author":"Cluny","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Gueye, A.B., Pryslawsky, Y., Trigo, J.M., Poulia, N., Delis, F., Antoniou, K., Loureiro, M., Laviolette, S.R., Vemuri, K., and Makriyannis, A. (2016). The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability. Int. J. Neuropsychopharmacol., 19.","DOI":"10.1093\/ijnp\/pyw068"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.10.040","article-title":"Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling","volume":"131","author":"Balla","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1038\/nutd.2013.9","article-title":"The cannabinoid Delta(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity","volume":"3","author":"Wargent","year":"2013","journal-title":"Nutr. Diabetes"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.phrs.2013.06.001","article-title":"NESS06SM reduces body weight with an improved profile relative to SR141716A","volume":"74","author":"Mastinu","year":"2013","journal-title":"Pharm. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.phrs.2016.08.012","article-title":"The novel cannabinoid antagonist SM-11 reduces hedonic aspect of food intake through a dopamine-dependent mechanism","volume":"113","author":"Fois","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/bs.mie.2017.06.025","article-title":"Metabolic Profiling of CB1 Neutral Antagonists","volume":"593","author":"Seltzman","year":"2017","journal-title":"Methods Enzym."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF00427475","article-title":"Effects of marihuana use on body weight and caloric intake in humans","volume":"49","author":"Greenberg","year":"1976","journal-title":"Psychopharmacology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0195-6663(88)80017-5","article-title":"Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory","volume":"11","author":"Foltin","year":"1988","journal-title":"Appetite"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1300\/J069v24n03_08","article-title":"Body mass index and marijuana use","volume":"24","author":"Warren","year":"2005","journal-title":"J. Addict. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.amjcard.2006.03.024","article-title":"Marijuana use, diet, body mass index, and cardiovascular risk factors (from the CARDIA study)","volume":"98","author":"Rodondi","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.amjmed.2013.03.002","article-title":"The impact of marijuana use on glucose, insulin, and insulin resistance among US adults","volume":"126","author":"Penner","year":"2013","journal-title":"Am. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.addbeh.2013.06.024","article-title":"Association between adolescent substance use and obesity in young adulthood: A group-based dual trajectory analysis","volume":"38","author":"Huang","year":"2013","journal-title":"Addict. Behav."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.2337\/dc12-2303","article-title":"Metabolic effects of chronic cannabis smoking","volume":"36","author":"Muniyappa","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Cobb, S., Bazargan, M., Smith, J., Del Pino, H.E., Dorrah, K., and Assari, S. (2019). Marijuana Use among African American Older Adults in Economically Challenged Areas of South Los Angeles. Brain Sci., 9.","DOI":"10.3390\/brainsci9070166"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/oby.20973","article-title":"Cannabis use in relation to obesity and insulin resistance in the Inuit population","volume":"23","author":"Ngueta","year":"2015","journal-title":"Obesity"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1017\/S1355617716000278","article-title":"Decision-Making Does not Moderate the Association between Cannabis Use and Body Mass Index among Adolescent Cannabis Users","volume":"22","author":"Ross","year":"2016","journal-title":"J. Int. Neuropsychol. Soc. Jins"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ije\/dyz044","article-title":"Are cannabis users less likely to gain weight? Results from a national 3-year prospective study","volume":"48","author":"Alshaarawy","year":"2019","journal-title":"Int. J. Epidemiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/PSY.0000000000000665","article-title":"Associations Between Cannabis Use and Cardiometabolic Risk Factors: A Longitudinal Study of Men","volume":"81","author":"Meier","year":"2019","journal-title":"Psychosom. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/add.14097","article-title":"Self-reported marijuana use over 25 years and abdominal adiposity: The Coronary Artery Risk Development in Young Adults (CARDIA) Study","volume":"113","author":"Bancks","year":"2018","journal-title":"Addiction"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.annepidem.2015.01.013","article-title":"Estimating the association between metabolic risk factors and marijuana use in U.S. adults using data from the continuous National Health and Nutrition Examination Survey","volume":"25","author":"Thompson","year":"2015","journal-title":"Ann. Epidemiol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/08897077.2015.1013204","article-title":"Bidirectional relationship between the body mass index and substance use in young men","volume":"37","author":"Studer","year":"2016","journal-title":"Subst. Abus."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Jin, L.Z., Rangan, A., Mehlsen, J., Andersen, L.B., Larsen, S.C., and Heitmann, B.L. (2017). Association Between Use of Cannabis in Adolescence and Weight Change into Midlife. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0168897"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/0269881118822173","article-title":"Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study","volume":"33","author":"Castro","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"109677","DOI":"10.1016\/j.pnpbp.2019.109677","article-title":"Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients","volume":"95","author":"Iruzubieta","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2018.02.050","article-title":"Effects of cannabis use on body mass, fasting glucose and lipids during the first 12months of treatment in schizophrenia spectrum disorders","volume":"199","author":"Scheffler","year":"2018","journal-title":"Schizophr. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/0269881116631652","article-title":"Cannabis use in people with severe mental illness: The association with physical and mental health--a cohort study. A Pharmacotherapy Monitoring and Outcome Survey study","volume":"30","author":"Bruins","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ctim.2017.07.002","article-title":"Cannabis use in people with Parkinson\u2019s disease and Multiple Sclerosis: A web-based investigation","volume":"33","author":"Kindred","year":"2017","journal-title":"Complement. Ther. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1753-0407.12958","article-title":"Lifetime marijuana use in relation to insulin resistance in lean, overweight, and obese US adults","volume":"12","author":"Ngueta","year":"2020","journal-title":"J. Diabetes"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"6278709","DOI":"10.1155\/2016\/6278709","article-title":"Cannabis Use as Risk or Protection for Type 2 Diabetes: A Longitudinal Study of 18 000 Swedish Men and Women","volume":"2016","author":"Danielsson","year":"2016","journal-title":"J. Diabetes Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Rissanen","year":"2005","journal-title":"Lancet"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/eurheartj\/ehn076","article-title":"Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: Two year results from the RIO-Europe Study","volume":"29","author":"Scheen","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial","volume":"295","author":"Aronne","year":"2006","journal-title":"JAMA"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.2337\/dc08-s258","article-title":"Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight\/obese patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program","volume":"31","author":"Despres","year":"2008","journal-title":"Diabetes Care"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ijo.2012.116","article-title":"CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans","volume":"37","author":"Bergholm","year":"2013","journal-title":"Int. J. Obes. (Lond.)"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(10)60935-X","article-title":"Rimonabant for prevention of cardiovascular events (CRESCENDO): A randomised, multicentre, placebo-controlled trial","volume":"376","author":"Topol","year":"2010","journal-title":"Lancet"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1475-2891-11-50","article-title":"Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant","volume":"11","author":"Heppenstall","year":"2012","journal-title":"Nutr. J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2337\/dc09-0455","article-title":"Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: The ARPEGGIO trial","volume":"33","author":"Hollander","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","article-title":"Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study","volume":"368","author":"Scheen","year":"2006","journal-title":"Lancet"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ijo.2010.38","article-title":"A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: Low-dose study","volume":"34","author":"Proietto","year":"2010","journal-title":"Int. J. Obes. (Lond.)"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/ijo.2010.21","article-title":"A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: A high-dose study","volume":"34","author":"Aronne","year":"2010","journal-title":"Int. J. Obes. (Lond.)"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/oby.2010.67","article-title":"A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet","volume":"18","author":"Wadden","year":"2010","journal-title":"Obesity"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cmet.2007.11.012","article-title":"The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake","volume":"7","author":"Addy","year":"2008","journal-title":"Cell Metab."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/0091270008314467","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: Results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers","volume":"48","author":"Addy","year":"2008","journal-title":"J. Clin. Pharm."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/0091270008317591","article-title":"Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers","volume":"48","author":"Addy","year":"2008","journal-title":"J. Clin. Pharm."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1463-1326.2009.01188.x","article-title":"A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes","volume":"12","author":"Kipnes","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.12141","article-title":"Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects","volume":"76","author":"Klumpers","year":"2013","journal-title":"Br. J. Clin. Pharm."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1545109707300157","article-title":"Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV\/AIDS-Infected Patients","volume":"6","author":"DeJesus","year":"2007","journal-title":"J. Int. Assoc. Physicians Aids Care (Chic.)"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/QAI.0b013e31811ed205","article-title":"Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep","volume":"45","author":"Haney","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/eat.22173","article-title":"Dronabinol in severe, enduring anorexia nervosa: A randomized controlled trial","volume":"47","author":"Andries","year":"2014","journal-title":"Int. J. Eat. Disord."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.clinthera.2015.07.023","article-title":"A 4-week pilot study with the cannabinoid receptor agonist dronabinol and its effect on metabolic parameters in a randomized trial","volume":"37","author":"Reichenbach","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_159","first-page":"261","article-title":"Efficacy and Safety of Appetite-Stimulating Medications in the Inpatient Setting","volume":"53","author":"Howard","year":"2019","journal-title":"Ann. Pharm."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/0003489415612801","article-title":"Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial","volume":"125","author":"Cote","year":"2016","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12630-017-0814-3","article-title":"A randomized-controlled trial of nabilone for the prevention of acute postoperative nausea and vomiting in elective surgery","volume":"64","author":"Levin","year":"2017","journal-title":"Can. J. Anaesth."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Rzepa, E., Tudge, L., and McCabe, C. (2015). The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers. Int. J. Neuropsychopharmacol., 19.","DOI":"10.1093\/ijnp\/pyv092"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Fataar, F., and Hammond, D. (2019). The Prevalence of Vaping and Smoking as Modes of Delivery for Nicotine and Cannabis among Youth in Canada, England and the United States. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16214111"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/her\/cyp027","article-title":"Cannabis and tobacco use: Where are the boundaries? A qualitative study on cannabis consumption modes among adolescents","volume":"25","author":"Akre","year":"2010","journal-title":"Health Educ. Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00406-019-00983-5","article-title":"New trends in cannabis potency in USA and Europe during the last decade (2008-2017)","volume":"269","author":"Chandra","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrendo.2009.197","article-title":"CB1 antagonists for obesity--what lessons have we learned from rimonabant?","volume":"5","author":"Despres","year":"2009","journal-title":"Nat. Reviews Endocrinol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ardp.200700255","article-title":"The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity","volume":"341","author":"Hagmann","year":"2008","journal-title":"Arch. Pharm. (Weinh.)"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.1016\/j.bmcl.2012.08.004","article-title":"JD-5006 and JD-5037: Peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities","volume":"22","author":"Chorvat","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Cinar, R., Iyer, M.R., Liu, Z., Cao, Z., Jourdan, T., Erdelyi, K., Godlewski, G., Szanda, G., Liu, J., and Park, J.K. (2016). Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. Jci Insight, 1.","DOI":"10.1172\/jci.insight.87336"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/jlcr.3433","article-title":"The syntheses of isotopically labelled CB-1 antagonists for the treatment of obesity","volume":"59","author":"Tran","year":"2016","journal-title":"J. Label. Comp. Radiopharm."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharm."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"113693","DOI":"10.1016\/j.bcp.2019.113693","article-title":"Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity","volume":"171","author":"Palomares","year":"2020","journal-title":"Biochem. Pharm."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","article-title":"Pharmacology of cannabinoid CB1 and CB2 receptors","volume":"74","author":"Pertwee","year":"1997","journal-title":"Pharm. Ther."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/bph.13497","article-title":"An update on PPAR activation by cannabinoids","volume":"173","year":"2016","journal-title":"Br. J. Pharm."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fnmol.2018.00487","article-title":"Cannabinoid Ligands Targeting TRP Channels","volume":"11","author":"Muller","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1126\/science.179.4071.391","article-title":"Delta-9-tetrahydrocannabinol: Localization in body fat","volume":"179","author":"Kreuz","year":"1973","journal-title":"Science"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/bph.12014","article-title":"Pharmacological modulation of the endocannabinoid signalling alters binge-type eating behaviour in female rats","volume":"169","author":"Scherma","year":"2013","journal-title":"Br. J. Pharm."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00280-017-3387-5","article-title":"A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: A focus on pharmacokinetic variability and pharmacodynamics","volume":"80","author":"Badowski","year":"2017","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40519-014-0132-5","article-title":"Effect of dronabinol therapy on physical activity in anorexia nervosa: A randomised, controlled trial","volume":"20","author":"Andries","year":"2015","journal-title":"Eat. Weight Disord."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jep.2006.02.001","article-title":"Cannabinoids in medicine: A review of their therapeutic potential","volume":"105","year":"2006","journal-title":"J. Ethnopharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0305-7372(82)80031-5","article-title":"Pharmacokinetics, metabolism and drug-abuse potential of nabilone","volume":"9","author":"Lemberger","year":"1982","journal-title":"Cancer Treat. Rev."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1016\/j.bmc.2018.08.003","article-title":"Oximes short-acting CB1 receptor agonists","volume":"26","author":"Malamas","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.bjp.0706414","article-title":"Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist","volume":"146","author":"Thomas","year":"2005","journal-title":"Br. J. Pharm."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/6\/855\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:35:36Z","timestamp":1760175336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/6\/855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":184,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["biom10060855"],"URL":"https:\/\/doi.org\/10.3390\/biom10060855","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,4]]}}}